Inventor · disambiguated record
Maria A. Argiriadi
Also filed as: ARGIRIADI MARIA · ARGIRIADI MARIA A · ARGIRIADI MARIA ANASTASIA
15 granted patents·17 pending applications·403 citations·filing 2007–2024
93Inventor score
Top patents by PatentIndex Score
32 records- 0197US9365579B2Tricyclic compoundsABBVIE INC·Filed 2015·Granted Jun 14, 2016·50 cites·15 claims
- 0297US7915388B2Interleukin-13 binding proteinsABBOTT LAB·Filed 2007·Granted Mar 29, 2011·96 cites·41 claims
- 0396US8962629B2Tricyclic compoundsWISHART NEIL·Filed 2009·Granted Feb 24, 2015·56 cites·53 claims
- 0495US8785639B2Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereofWISHART NEIL·Filed 2010·Granted Jul 22, 2014·57 cites·9 claims
- 0595US8008481B2Indazole compoundsERICSSON ANNA M·Filed 2007·Granted Aug 30, 2011·112 cites·8 claims
- 0692US9592293B2Interleukin-13 binding proteinsABBVIE INC·Filed 2013·Granted Mar 14, 2017·18 cites·13 claims
- 0787US11344621B2Interleukin-13 binding proteinsABBVIE INC·Filed 2018·Granted May 31, 2022·2 cites·35 claims
- 0886US10086076B2Interleukin-13 binding proteinsABBVIE INC·Filed 2017·Granted Oct 2, 2018·4 cites·11 claims
- 0983US10508113B2Inhibitors of tyrosine kinase 2 mediated signalingABBVIE INC·Filed 2019·Granted Dec 17, 2019·3 cites·30 claims
- 1078US8604177B2Interleukin-13 binding proteinsWU CHENGBIN·Filed 2011·Granted Dec 10, 2013·3 cites·30 claims
- 1176US2023082167A1Novel tricyclic compoundsABBVIE INC·Filed 2022·Application pending·0 cites
- 1269US10106501B2Nuclear receptor modulatorsABBVIE INC·Filed 2016·Granted Oct 23, 2018·1 cites·53 claims
- 1369US2023066771A1Nuclear receptor modulatorsABBVIE INC·Filed 2021·Application pending·0 cites
- 1468US2024360099A1Nicotinamide ripk1 inhibitorsABBVIE INC·Filed 2024·Application pending·0 cites
- 1567US11767310B2Nicotinamide RIPK1 inhibitorsABBVIE INC·Filed 2022·Granted Sep 26, 2023·0 cites·8 claims
- 1666US10093733B2LRP-8 binding dual variable domain immunoglobulin proteinsABBVIE INC·Filed 2015·Granted Oct 9, 2018·1 cites·25 claims
- 1765US2021130293A1Nuclear receptor modulatorsABBVIE INC·Filed 2019·Application pending·0 cites
- 1865US2021061813A1Novel tricyclic compoundsABBVIE INC·Filed 2019·Application pending·0 cites
- 1965US2022289858A1Anti-cd40 antibodies and uses thereofABBVIE INC·Filed 2021·Application pending·0 cites
- 2061US2018291029A1Novel tricyclic compoundsABBVIE INC·Filed 2017·Application pending·0 cites
- 2159US2013216497A1Novel tricyclic compoundsWISHART NEIL·Filed 2013·Application pending·0 cites
- 2257US2016326181A1Novel tricyclic compoundsABBVIE INC·Filed 2016·Application pending·0 cites
- 2357US2020255423A1Inhibitors of tyrosine kinase 2 mediated signalingABBVIE INC·Filed 2019·Application pending·0 cites
- 2456US2019055196A1Nuclear receptor modulatorsABBVIE INC·Filed 2018·Application pending·0 cites
- 2555US2016222020A1Novel tricyclic compoundsABBVIE INC·Filed 2016·Application pending·0 cites
- 2653US2019359725A1Anti-cd40 antibodies and uses thereofABBVIE INC·Filed 2018·Application pending·0 cites
- 2751US2009202557A1Compositions and methods for crystallizing antibody fragmentsARGIRIADI MARIA A·Filed 2009·Application pending·0 cites
- 2851US2012053345A1Indazole CompoundsERICSON ANNA M·Filed 2011·Application pending·0 cites
- 2951US2014349970A1Novel tricyclic compoundsWISHART NEIL·Filed 2014·Application pending·0 cites
- 3050US10160748B2Indazolones as modulators of tnf signalingABBVIE INC·Filed 2017·Granted Dec 25, 2018·0 cites·20 claims
- 3142US2016304496A1Indazolones as modulators of tnf signalingABBVIE INC·Filed 2016·Application pending·0 cites
- 3241US9115151B2Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereofGEORGE DAWN M·Filed 2014·Granted Aug 25, 2015·0 cites·19 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →